1800-272-662
Shopping Cart 0
countryflagAU
Login

INVEX Therapeutics Ltd

Healthcare AU IXC

0.105AUD
-(-%)

Last update at 2026-03-13T04:49:00Z

Day Range

0.100.10
LowHigh

52 Week Range

0.070.18
LowHigh

Fundamentals

  • Previous Close 0.10
  • Market Cap7.89M
  • Volume5341
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.23M
  • Revenue Per Share TTM0.003
  • Gross Profit TTM 0.23M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -0.47687M -2.85400M -7.74986M -3.95314M -2.28391M
Minority interest - - - - -
Net income -0.47687M -1.64200M -7.74986M -3.95314M -2.28391M
Selling general administrative 0.72M 1.17M 1.29M 0.90M 0.99M
Selling and marketing expenses 0.02M 0.14M - - -
Gross profit 0.23M 1.21M 0.46M 0.18M -
Reconciled depreciation - - - - -
Ebit - -2.85400M -17.52623M -8.27470M -4.88539M
Ebitda - -0.72000M -8.97929M -4.24168M -2.44270M
Depreciation and amortization 0.71M 2.13M 8.55M 4.03M 2.44M
Non operating income net other - - - - -
Operating income -0.70930M -2.13400M -8.54694M -4.03302M -2.44270M
Other operating expenses 0.94M 3.35M 9.01M 4.22M 2.44M
Interest expense - - - 0.08M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.23M 0.49M 0.80M 0.08M 0.16M
Net interest income 0.23M 0.49M 0.80M 0.08M 0.16M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -1.21200M -9.34402M -4.11290M -2.44270M
Total revenue 0.23M 1.21M 0.46M 0.18M 0.16M
Total operating expenses 0.94M 3.35M 8.98M 4.24M 2.44M
Cost of revenue - - - - -
Total other income expense net 0.23M 0.49M 0.43M 0.21M 0.16M
Discontinued operations - - - - -
Net income from continuing ops -0.47687M -1.64181M -7.74986M -3.95314M -2.28391M
Net income applicable to common shares -0.47687M -1.64181M -7.74986M -3.95314M -2.28391M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 5.47M 6.12M 22.80M 29.49M 32.74M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - -
Total liab 0.22M 0.43M 1.57M 1.00M 0.66M
Total stockholder equity 5.25M 5.69M 21.23M 28.48M 32.08M
Deferred long term liab - - - - -
Other current liab - 0.43M 0.43M 0.87M 0.65M
Common stock - 22.41M 36.41M 36.41M 36.41M
Capital stock 22.41M - 36.41M 36.41M 36.41M
Retained earnings -19.69798M -19.22112M -17.57931M -9.82945M -5.87631M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 5.38M 6.03M 22.47M 29.34M 32.72M
Cash and equivalents - - - - -
Total current liabilities 0.22M 0.43M 1.57M 1.00M 0.66M
Current deferred revenue - - - - -
Net debt - -6.02507M -22.47024M -29.33938M -32.71609M
Short term debt - - 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - -18.83412M -26.58398M -30.53712M
Property plant equipment - - - - -
Total current assets 5.47M 6.12M 22.80M 29.49M 32.74M
Long term investments - - - - -
Net tangible assets - - - 28.48M 32.08M
Short term investments - - - - -
Net receivables - 0.09M 0.33M 0.15M 0.02M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.17M 0.00560M 1.14M 0.14M 0.01M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 2.50M 2.40M 1.90M 1.54M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00000M - 0.00000M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - 0.00000M 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.00000M - - - -
Change to liabilities - - - 0.35M -0.05433M
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities 0.00000M -14.00116M 0.00000M 0.00000M 8.09M
Change to operating activities - - - - -
Net income -0.47687M -1.64181M -7.74986M -3.95314M -2.28391M
Change in cash -0.65001M -16.44517M -6.86914M -3.37671M 6.42M
Begin period cash flow 6.03M 22.47M 29.34M 32.72M 26.30M
End period cash flow 5.38M 6.03M 22.47M 29.34M 32.72M
Total cash from operating activities -0.65257M -2.44401M -6.86914M -3.37671M -1.67824M
Issuance of capital stock - - - - 8.65M
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.00219M 0.24M -0.18785M -0.12452M 0.10M
Sale purchase of stock - -14.00116M 0.00000M 0.00000M -0.55367M
Other cashflows from financing activities 0.00000M -14.00116M 0.00000M 0.00000M -0.55367M
Change to netincome - - - 0.36M 0.56M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.00219M 0.24M -0.18785M -0.12452M 0.10M
Stock based compensation 0.02M 0.14M 0.48M 0.35M 0.56M
Other non cash items -0.18981M -1.04076M 0.59M 0.35M -0.05274M
Free cash flow -0.65257M -2.44401M -6.86914M -3.37671M -1.67824M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
IXC
INVEX Therapeutics Ltd		 - -% 0.10 - - 34.45 1.74 -1.3322
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Subiaco, Australia.

INVEX Therapeutics Ltd

38 Rowland Street, Subiaco, WA, Australia, 6008

Key Executives

Name Title Year Born
Ms. Narelle Warren B.Com., L.L.B., B.Com, LLB CFO & Company Sec. NA
Prof. Alexandra Jean Sinclair Exec. Director & Chief Scientific Officer NA
Dr. Thomas Duthy M.B.A., Ph.D. Exec. Director NA
Ms. Carol Parish Chief Operating Officer NA
Ms. Narelle Warren B.Com., L.L.B., B.Com, LLB CFO & Company Secretary NA
Dr. Thomas Duthy M.B.A., Ph.D. Executive Director NA
Ms. Narelle Warren B.Com., L.L.B., B.Com, LLB CFO & Company Secretary NA
Dr. Thomas Duthy M.B.A., Ph.D. Executive Director NA
Ms. Narelle Warren B.Com., L.L.B., B.Com, LLB CFO & Company Secretary NA
Dr. Thomas Duthy M.B.A., Ph.D. Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.